Webinar | Women’s Nutrition: Nourishing Womanhood From Pregnancy To Menopause
11 September | 12 PM ET: Register Now

Instagram X-twitter Linkedin-in Youtube
GET IN TOUCH

Avisi Technologies

Avisi Technologies is an operator of a medical device company intended to treat glaucoma
2017
California, United States

www.avisitech.com

Drug Delivery and DevicesHealthcareNanotechnologyOpthalmic
  • Drug Delivery and Devices
  • Healthcare
  • Nanotechnology
  • Opthalmic
Innovation
Investment Funding
People
About
Products
Future Plan
News

Innovation

Industry Problem

Glaucoma drainage devices can cause tissue damage, scarring and inconsistent pressure control.

R&D Focus

Nanotechnology-based glaucoma implants and aqueous-humor drainage.

Innovative Solution

VisiPlate uses an ultrathin nanostructured implant designed to drain eye fluid while minimizing tissue disruption.

Investment Funding

Last Funding Stage

Seed

Total Funding Amount

$7.5M

Last Funding Amount

$4.06M

Last Funding Date

10-01-2023

Startup Stage

Early Stage

Lead Investors

Gaingels, America's Seed Fund, Accanto Partners

People

Founders

  • Rui Jing Jiang
  • Brandon Kao

CEO

  • Rui Jing Jiang

About

Avisi Technologies is an operator of a medical device company intended to treat glaucoma

Products

Product

VisiPlate and VisiPlate-S glaucoma implants.

Star Product

VisiPlate, because it is the lead implant addressing pressure control in glaucoma.

Demo Product or Complete Product?

Clinical and regulatory development stage; not yet a broadly commercial product.

Future Plan

Market Expansion

Funding supports clinical development and future US commercialization.

Investment Funding

Raised a $10.7 million Series A; the company reports total funding of approximately $21.7 million.

Something missing or incorrect on this page? Help us enrich this information

Claim Now and Contribute